Vanguard Investments Australia
CYTK icon

Vanguard Investments Australia’s Cytokinetics CYTK Stock Holding History

Vanguard Investments Australia’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
29,753
+790
+3% +$56.7K 0.01% 821
2026
Q1 		$1.91M Buy
+28,963
New +$1.84M 0.01% 873

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Investments Australia's CYTK Position: Q2 2026 in Review

Vanguard Investments Australia increased its Cytokinetics (CYTK) stake by 2.7% in Q2 2026, buying an estimated $56.7K and bringing the position to 29,753 shares worth $2.53M. The position accounts for 0.01% of the portfolio, ranked #821.

Vanguard Investments Australia first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Investments Australia held 29,753 shares of Cytokinetics worth $2.53M as of Q2 2026.
  • Vanguard Investments Australia bought 790 Cytokinetics shares in Q2 2026, an estimated $56.7K.
  • Cytokinetics made up 0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #821 holding.
  • Vanguard Investments Australia first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.